Meadow Creek Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Meadow Creek Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$27K	Hold	336	–	–	﹤0.01%	1305
2019 Q2	$32K	Buy	336 +140	+71%	+$12.1K	﹤0.01%	1306
2019 Q1	$17K	Sell	196 -56	-22%	-$4.65K	﹤0.01%	1322
2018 Q4	$14K	Buy	+252	New	+$15.4K	﹤0.01%	1288

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meadow Creek Investment Management's RETA Position: Q3 2019 in Review

Meadow Creek Investment Management held its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) position steady in Q3 2019 at 336 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

Meadow Creek Investment Management first reported a position in RETA in Q4 2018 and has held it in 4 quarters since. The position peaked at $32K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

Meadow Creek Investment Management held 336 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $27K as of Q3 2019.
Meadow Creek Investment Management left its Reata Pharmaceuticals, Inc. Class A Common Stock share count unchanged in Q3 2019.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1305 holding.
Meadow Creek Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and has held it in 4 quarters since.
Meadow Creek Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $32K in Q2 2019.
164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.